Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

Peter D. Cole,Christine Mauz-Körholz,Maurizio Mascarin,Gérard Michel,Stacy Cooper,Auke Beishuizen,Kasey J. Leger,Loredana Amoroso,Salvatore Buffardi,Charlotte Rigaud,Markus Puhlmann,Stephen Francis,Mariana Sacchi,Richard A. Drachtman,Paul Harker-Murray,Thierry Leblanc,Stephen Daw,Kara M. Kelly

Nivolumab and brentuximab vedotin (BV)-based, response‐adapted treatment in children, adolescents, and young adults (CAYA) with standard-risk relapsed/refractory classical Hodgkin lymphoma (R/R cHL): Primary analysis.

2020

Peter D. Cole
Christine Mauz-Körholz
Maurizio Mascarin
Gérard Michel
Stacy Cooper
Auke Beishuizen
Kasey J. Leger
Loredana Amoroso
Salvatore Buffardi
Charlotte Rigaud
Markus Puhlmann
Stephen Francis
Mariana Sacchi
Richard A. Drachtman
Paul Harker-Murray
Thierry Leblanc
Stephen Daw
Kara M. Kelly

8013Background: Outcomes for younger patients (pts) with R/R cHL are poor, particularly for those without complete metabolic response (CMR) before autologous transplant (auto-HCT). Nivolumab + BV h...

Keywords:

Oncology
Physical therapy
Standard Risk
Internal medicine
early adolescents
Nivolumab
Brentuximab vedotin
Young adult
Classical Hodgkin lymphoma
Medicine
relapsed refractory

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations